Association of clinical variables with RFS
| Variables . | HR . | P value . |
|---|---|---|
| Gender | — | .39 |
| Male vs female | 1.69 (0.5-1.78) | — |
| Age | — | .63 |
| >70 vs <55 | 1.69 (0.57,5.05) | — |
| 55-70 vs <55 | 1.31 (0.45,3.84) | — |
| Prior lines of therapy, n | — | .55 |
| 3-4 vs >4 | 1.03 (0.32-3.34) | — |
| 1-2 vs >4 | 0.6 (0.17-2.14) | — |
| Time from diagnosis to initial vemurafenib therapy, y | — | .82 |
| >15 vs <5 | 0.93 (0.29-2.94) | — |
| 5-15 vs <5 | 0.72 (0.24-2.16) | — |
| History of splenectomy | — | .64 |
| Yes vs no | 1.35 (0.39-4.72) | — |
| Type of response (best response) | — | .34 |
| CR vs PR | 1.55 (0.62-3.89) | — |
| Cumulative vemurafenib dose (mg) | — | .0005 |
| >230 000 vs <150 000 | 7.75 (2.23-26.87) | — |
| 150 000-230 000 vs <150 000 | 1.53 (0.51-4.54) | — |
| Duration of treatment | — | .08 |
| >90 d vs ≤90 d | 2.48 (0.88-7.01) | — |
| Variables . | HR . | P value . |
|---|---|---|
| Gender | — | .39 |
| Male vs female | 1.69 (0.5-1.78) | — |
| Age | — | .63 |
| >70 vs <55 | 1.69 (0.57,5.05) | — |
| 55-70 vs <55 | 1.31 (0.45,3.84) | — |
| Prior lines of therapy, n | — | .55 |
| 3-4 vs >4 | 1.03 (0.32-3.34) | — |
| 1-2 vs >4 | 0.6 (0.17-2.14) | — |
| Time from diagnosis to initial vemurafenib therapy, y | — | .82 |
| >15 vs <5 | 0.93 (0.29-2.94) | — |
| 5-15 vs <5 | 0.72 (0.24-2.16) | — |
| History of splenectomy | — | .64 |
| Yes vs no | 1.35 (0.39-4.72) | — |
| Type of response (best response) | — | .34 |
| CR vs PR | 1.55 (0.62-3.89) | — |
| Cumulative vemurafenib dose (mg) | — | .0005 |
| >230 000 vs <150 000 | 7.75 (2.23-26.87) | — |
| 150 000-230 000 vs <150 000 | 1.53 (0.51-4.54) | — |
| Duration of treatment | — | .08 |
| >90 d vs ≤90 d | 2.48 (0.88-7.01) | — |